chr19-33302315-G-T
Variant summary
Our verdict is Uncertain significance. Variant got 0 ACMG points: 2P and 2B. PM2BP4_Moderate
The NM_004364.5(CEBPA):c.100C>A(p.Pro34Thr) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000028 in 1,428,720 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 13/20 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★★).
Frequency
Consequence
NM_004364.5 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Uncertain_significance. Variant got 0 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
CEBPA | NM_004364.5 | c.100C>A | p.Pro34Thr | missense_variant | 1/1 | ENST00000498907.3 | NP_004355.2 | |
CEBPA | NM_001287424.2 | c.205C>A | p.Pro69Thr | missense_variant | 1/1 | NP_001274353.1 | ||
CEBPA | NM_001287435.2 | c.58C>A | p.Pro20Thr | missense_variant | 1/1 | NP_001274364.1 | ||
CEBPA | NM_001285829.2 | c.-258C>A | 5_prime_UTR_variant | 1/1 | NP_001272758.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
CEBPA | ENST00000498907.3 | c.100C>A | p.Pro34Thr | missense_variant | 1/1 | 6 | NM_004364.5 | ENSP00000427514.1 |
Frequencies
GnomAD3 genomes AF: 0.00000661 AC: 1AN: 151326Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.0000155 AC: 1AN: 64452Hom.: 0 AF XY: 0.0000269 AC XY: 1AN XY: 37192
GnomAD4 exome AF: 0.00000235 AC: 3AN: 1277394Hom.: 0 Cov.: 33 AF XY: 0.00000318 AC XY: 2AN XY: 628420
GnomAD4 genome AF: 0.00000661 AC: 1AN: 151326Hom.: 0 Cov.: 32 AF XY: 0.00 AC XY: 0AN XY: 73882
ClinVar
Submissions by phenotype
Acute myeloid leukemia Uncertain:2
Uncertain significance, criteria provided, single submitter | clinical testing | Baylor Genetics | Aug 30, 2023 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Apr 19, 2023 | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant  is likely to be tolerated. ClinVar contains an entry for this variant (Variation ID: 1035441). This variant has not been reported in the literature in individuals affected with CEBPA-related conditions. This variant is present in population databases (no rsID available, gnomAD 0.008%). This sequence change replaces proline, which is neutral and non-polar, with threonine, which is neutral and polar, at codon 34 of the CEBPA protein (p.Pro34Thr). - |
Inborn genetic diseases Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Jun 11, 2021 | The c.100C>A (p.P34T) alteration is located in exon 1 (coding exon 1) of the CEBPA gene. This alteration results from a C to A substitution at nucleotide position 100, causing the proline (P) at amino acid position 34 to be replaced by a threonine (T). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at